Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 1.14
HSKA's Cash to Debt is ranked higher than
58% of the 896 Companies
in the Global Biotechnology industry.

( Industry Median: 171.30 vs. HSKA: 1.14 )
HSKA' s 10-Year Cash to Debt Range
Min: 0.27   Max: No Debt
Current: 1.14

Equity to Asset 0.50
HSKA's Equity to Asset is ranked higher than
62% of the 759 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. HSKA: 0.50 )
HSKA' s 10-Year Equity to Asset Range
Min: 0.02   Max: 0.78
Current: 0.5

0.02
0.78
Z-Score: -0.61
M-Score: -2.14
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Revenue Growth (%) 3.00
HSKA's Revenue Growth (%) is ranked higher than
72% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: -0.40 vs. HSKA: 3.00 )
HSKA' s 10-Year Revenue Growth (%) Range
Min: -16.9   Max: 10.4
Current: 3

-16.9
10.4
EBITDA Growth (%) -24.60
HSKA's EBITDA Growth (%) is ranked higher than
67% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -10.60 vs. HSKA: -24.60 )
HSKA' s 10-Year EBITDA Growth (%) Range
Min: -63.9   Max: 27.7
Current: -24.6

-63.9
27.7
» HSKA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

HSKA Guru Trades in Q1 2013

Mario Gabelli 64,635 sh (+4.02%)
Jim Simons 80,680 sh (-10.24%)
» More
Q2 2013

HSKA Guru Trades in Q2 2013

Mario Gabelli 64,135 sh (-0.77%)
Jim Simons 74,280 sh (-7.93%)
» More
Q3 2013

HSKA Guru Trades in Q3 2013

Jim Simons 81,780 sh (+10.1%)
Mario Gabelli 60,435 sh (-5.77%)
» More
Q4 2013

HSKA Guru Trades in Q4 2013

Mario Gabelli 61,935 sh (+2.48%)
Jim Simons 70,380 sh (-13.94%)
» More
» Details

Insider Trades

Latest Guru Trades with HSKA

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Mario Gabelli 2012-12-31 Add 29.08%$7.96 - $9.54 $ 11.937%62135
Mario Gabelli 2012-09-30 Add 50.73%$7.78 - $11.3 $ 11.927%48135
Mario Gabelli 2012-06-30 Add 56.54%$10.9 - $12.85 $ 11.90%31935
Mario Gabelli 2011-06-30 Add 31.85%$6.12 - $9.96 $ 11.946%20700
Mario Gabelli 2011-03-31 New Buy$4.79 - $6.83 $ 11.999%15700
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.50
HSKA's P/B is ranked higher than
92% of the 787 Companies
in the Global Biotechnology industry.

( Industry Median: 4.51 vs. HSKA: 1.50 )
HSKA' s 10-Year P/B Range
Min: 0.22   Max: 75.45
Current: 1.5

0.22
75.45
P/S 0.90
HSKA's P/S is ranked higher than
98% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: 10.38 vs. HSKA: 0.90 )
HSKA' s 10-Year P/S Range
Min: 0.12   Max: 2.44
Current: 0.9

0.12
2.44
EV-to-EBIT 250.00
HSKA's EV-to-EBIT is ranked lower than
83% of the 478 Companies
in the Global Biotechnology industry.

( Industry Median: 20.00 vs. HSKA: 250.00 )
HSKA' s 10-Year EV-to-EBIT Range
Min: 4.8   Max: 149.8
Current: 250

4.8
149.8
Shiller P/E 101.40
HSKA's Shiller P/E is ranked higher than
94% of the 175 Companies
in the Global Biotechnology industry.

( Industry Median: 38.60 vs. HSKA: 101.40 )
HSKA' s 10-Year Shiller P/E Range
Min: 1.86   Max: 100.5
Current: 101.4

1.86
100.5

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.10
HSKA's Dividend Yield is ranked lower than
51% of the 164 Companies
in the Global Biotechnology industry.

( Industry Median: 1.15 vs. HSKA: 1.10 )
HSKA' s 10-Year Dividend Yield Range
Min: 0.79   Max: 3.71
Current: 1.1

0.79
3.71
Yield on cost (5-Year) 1.10
HSKA's Yield on cost (5-Year) is ranked lower than
54% of the 169 Companies
in the Global Biotechnology industry.

( Industry Median: 1.27 vs. HSKA: 1.10 )
HSKA' s 10-Year Yield on cost (5-Year) Range
Min: 0.79   Max: 3.71
Current: 1.1

0.79
3.71
Share Buyback Rate -3.10
HSKA's Share Buyback Rate is ranked higher than
90% of the 696 Companies
in the Global Biotechnology industry.

( Industry Median: -11.30 vs. HSKA: -3.10 )
HSKA' s 10-Year Share Buyback Rate Range
Min: 1.8   Max: -29.6
Current: -3.1

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 2.70
HSKA's Price/Tangible Book is ranked higher than
80% of the 727 Companies
in the Global Biotechnology industry.

( Industry Median: 6.00 vs. HSKA: 2.70 )
HSKA' s 10-Year Price/Tangible Book Range
Min: 0.3   Max: 261.43
Current: 2.7

0.3
261.43
Price/DCF (Projected) 1.30
HSKA's Price/DCF (Projected) is ranked higher than
86% of the 205 Companies
in the Global Biotechnology industry.

( Industry Median: 2.80 vs. HSKA: 1.30 )
HSKA' s 10-Year Price/DCF (Projected) Range
Min: 0.57   Max: 20.11
Current: 1.3

0.57
20.11
Price/Median PS Value 1.30
HSKA's Price/Median PS Value is ranked higher than
55% of the 717 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. HSKA: 1.30 )
HSKA' s 10-Year Price/Median PS Value Range
Min: 0.23   Max: 18.7
Current: 1.3

0.23
18.7
Earnings Yield (Greenblatt) 0.40
HSKA's Earnings Yield (Greenblatt) is ranked lower than
73% of the 379 Companies
in the Global Biotechnology industry.

( Industry Median: 4.40 vs. HSKA: 0.40 )
HSKA' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.4   Max: 20.7
Current: 0.4

0.4
20.7
Forward Rate of Return (Yacktman) 3.24
HSKA's Forward Rate of Return (Yacktman) is ranked higher than
91% of the 669 Companies
in the Global Biotechnology industry.

( Industry Median: -9.87 vs. HSKA: 3.24 )
HSKA' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -17.2   Max: 2.1
Current: 3.24

-17.2
2.1

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Heska Corporation was founded as Paravax, Inc. in 1988 and conducted research on vaccines to prevent infections by parasites. It was originally incorporated in California in 1988, and it subsequently incorporated in Delaware in 1997. It develops, manufactures, markets, sells and supports veterinary products. The Company's core focus is on the canine and feline companion animal health markets where it strives to provide high value products. The Company's business is comprised of two reportable segments, Core Companion Animal Health and other Vaccines, Pharmaceuticals and Products. The Core Companion Animal Health segment ('CCA') includes diagnostic instruments and supplies as well as single use diagnostic and other tests, vaccines and pharmaceuticals, mainly for canine and feline use. These products are sold directly by it as well as through independent third-party distributors and other distribution relationships. The Other Vaccines, Pharmaceuticals and Products segment ('OVP') includes private label vaccine and pharmaceutical production, mainly for cattle but also for other animals including small mammals and fish. All OVP products are sold by third parties under third party labels. The Company presently sells a variety of companion animal health products and services, among the most significant of which are the following: veterinary instruments; point-of-care diagnostic and other tests; veterinary diagnostic laboratory products and services; pharmaceuticals and supplements; vaccines and other biologicals. It offers a line of veterinary diagnostic and other instruments. Its line of veterinary instruments includes the following: Blood Chemistry; Hematology; Blood Gases; and IV Pumps. The DRI-CHEM 4000 Veterinary Chemistry Analyzer is a robust system that uses dry slide technology for blood chemistry and electrolyte analysis and has the ability to run 22 tests at a time with a single blood sample. The HEMATRUE Veterinary Hematology Analyzer is an easy-to-use blood analyzer that measures such key parameters as white blood cell count, red blood cell count, platelet count and hemoglobin levels in animals. The VET/IV 2.2 infusion pump is a compact, affordable IV pump that allows veterinarians to easily provide regulated infusion of fluids, drugs or nutritional products for their patients. The VET/IV 2.2 infusion pump is a compact, affordable IV pump that allows veterinarians to easily provide regulated infusion of fluids, drugs or nutritional products for their patients. Renal damage is a cause of death in both dogs and cats. Several inflammatory, infectious or neoplastic diseases can damage an animal's kidneys. Allergy is common in companion animals, and it has been estimated to affect approximately 10% to 15% of dogs. The Company sells kits to conduct blood testing using its ALLERCEPT Definitive Allergen Panels to third-party veterinary diagnostic laboratories outside of the United States. It has veterinary diagnostic laboratories i

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide